Pacific Oncology Hematology Associates
Pacific Oncology Hematology Associates
endcapYour VisitmiddleYour TeammiddleNewly DiagnosedmiddleTypes of CancermiddleCancer TreatmentmiddleTestingmiddleCancer NewsmiddleClinical TrialsmiddleSupport & Resourcesendcap
Welcome Our Pledge Our Mission Appointments Emergencies & Phone Calls Insurance & Billing Locations Prescription Refills Patient Bill of Rights Patient/Practice Expectations HIPAA Acknowledgement New Patient Information Privacy Policy Website Information
Our Physicians Our Nurse Practitioners Our Managers Employment Opportunites
What is Cancer? Diagnosing Cancer Introduction to Cancer Treatment Optimizing Treatment Questions to Ask A Word about Clinical Trials Getting a Second Opinion
General Cancer Information Bladder Cancer Bone Cancer Brain Cancer Breast Cancer Cervical Cancer Colon Cancer Esophageal Cancer Gastric Cancer Head & Neck Cancer Hodgkin's Lymphoma Leukemia Lung Cancer Melanoma Multiple Myeloma
More...
Myelodysplastic Syndrome Non-Hodgkin's Lymphoma Ovarian Cancer Pancreatic Cancer Prostate Cancer Rectal Cancer Renal Cancer Sarcoma Uterine Cancer Skin Cancer Testicular Cancer Thyroid Cancer
Treatment Overview Chemotherapy Radiation Therapy Surgery Hormonal Therapy Targeted Therapy Stem Cell Transplantation Side Effects of Treatment Complementary & Alternative
Overview Screening Tools Diagnostic & Monitoring Tests
Latest Cancer News Anal Cancer Bladder Cancer Bone Cancer Brain & CNS Breast Cancer Cervical Cancer Colon Cancer Complementary Alternative Medicine Esophageal Cancer Gastric Cancer Gene Therapy Head & Neck Cancer HIV Related Cancers Hodgkin's Lymphoma
More...
Leukemia Liver Cancer Lung Cancer - Non-Small Cell Lung Cancer - Small Cell Malignant Mesothelioma Melanoma Multiple Myeloma Myelodysplastic Syndromes Neuroblastoma Non-Hodgkin's Lymphoma Ovarian Cancer Pancreatic Cancer Prostate Cancer Rectal Cancer Renal Cancer Retinoblastoma
More...
Sarcoma Screening & Prevention Skin Cancer Stem Cell Transplant Supportive Care Testicular Cancer Thyroid Cancer Uterine Cancer Vaginal Cancer
Introduction What Are Clinical Trials? Phases of Clinical Trials How Are Clinical Trials Conducted? Clinical Trials Safeguards Participating in Clinical Trials The Cost of Clinical Trials Finding Specific Clinical Trials The Future of Clinical Trials Clinical Trials Database
Overview The Cancer Journey Caregivers Healing Environments Support Groups Journaling Birth Control and Sexuality Home Health Financial & Insurance Issues Advanced Directives Inspiration Movement & Exercise Life after Treatment Online Resources
floatmenu_left Home Home   Drug Dictionary Drug Dictionary   Cancer Dictionary Cancer Dictionary   Links Links   Contact Us Contact Us floatmenu_right
Pacific Oncology Hematology Associates
E-mail this page   Print this page
Section Title

Uterine Cancer

Overview

The uterus is the female reproductive organ where the unborn baby grows and develops until birth. This muscular organ is connected to the vagina by the cervix and contains entrances for the two fallopian tubes, which transfer eggs from the ovaries. The uterus is a highly hormone sensitive organ with monthly bleeding and shedding cycles (menstruation) in the absence of pregnancy. The growth of the most common uterine cancer, adenocarcinoma, is also sensitive to female hormones. Uterine cancer usually arises from the surface of the uterus or endometrium and less frequently from glands in the uterus. For most women, uterine cancer is brought to medical attention because of unanticipated or problematic bleeding from the uterus, usually occurring after menopause. Fortunately, 80% of women diagnosed after developing abnormal bleeding will have cancer limited to the uterus (stage I and II) and a high proportion are cured.

Uterine (endometrial) cancer is one of the most common gynecologic cancers in women, with 36,100 new cases each year. The incidence of uterine cancer would be even higher if it weren’t for the relatively large number of hysterectomies performed for non-cancerous reasons. It is estimated that approximately 6,500 women will die of uterine cancer in the U.S. in 2001. There has been an increase in the incidence of uterine cancer since the mid 1970s, which has been attributed to the use of hormone replacement therapy. Surgery is the primary treatment for uterine cancer and approximately 82% of women survive 5 years after diagnosis. For more information about the cause of uterine cancer and programs for early detection, go to Prevention and Screening.

Currently, a dilation and curettage (D&C) is the most reliable method for diagnosing uterine cancer. During a D&C, a sample of the cells lining the uterus is removed for examination under a microscope to determine if cancer is present. Following a diagnosis of uterine cancer, additional tests are performed on the cancer cells to determine the stage of the cancer in order to provide optimal treatment.

There are several types of uterine cancer, which vary based on their appearance under the microscope. The most common type of uterine cancer is adenocarcinoma. Other variants of uterine cancer that behave more aggressively include serous carcinoma, uterine clear cell carcinoma and mixed type. These cancers, stage for stage, have a worse outcome than adenocarcinoma. Outcomes following treatment of adenocarcinoma can also be affected by the appearance of cancer when examined under the microscope. Doctors grade adenocarcinomas, as poorly, moderately or well differentiated. These terms describe how closely the cancer resembles normal cells of the uterus. In general, the less differentiated the cells, the more aggressive the cancer. More poorly differentiated cancers have a higher rate of recurrence. The reason doctors are interested in this is that more or better treatments may be indicated for patients with more aggressive cancers.

In addition to the type and grade of the cancer, the stage or extent of spread of cancer is the most useful predictor of survival and is relevant for treatment planning. Currently, surgery to remove the uterus, ovaries and lymph nodes is relied upon to determine the stage of the cancer.

Other tests that may be utilized to help stage the cancer include magnetic resonance imaging (MRI) scans and ultrasound. The most common method for examining the uterus is with transvaginal sonography. During transvaginal sonography, an ultrasound apparatus is passed through the vagina in order to examine the uterus. Another test, sonohysterography, improves the accuracy of sonography by first infusing a salt solution into the uterus through the cervix. MRI scans can also be useful in determining whether the lymph nodes are involved with cancer and may prevent the need for lymph node dissection.

In order to learn more about the most recent information available concerning the treatment of uterine cancer, click on the appropriate stage.

Stage I: Cancer does not spread outside the body of the uterus.

Stage II: Cancer involves the body of the uterus and the cervix.

Stage III: Cancer extends outside the uterus, but is confined to the pelvis.

Stage IV: Cancer involves the bladder or bowel or distant sites.

Recurrent: Cancer has returned after initial treatment.